An algorithm for the management of hepatic encephalopathy

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 2, 2007, Pages 32-47

  Mullen, Kevin D ^a   Ferenci, Peter ^b   Bass, Nathan M ^c   Leevy, Carroll B ^d   Keeffe, Emmet B ^e  

^a METROHEALTH MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Hepatic encephalopathy; Pharmacotherapy; Treatment guidelines

Indexed keywords

ACARBOSE; AMMONIA; ANTIBIOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; CARNITINE; DISACCHARIDE; FLUMAZENIL; LACTITOL; LACTULOSE; METHYSERGIDE; METRONIDAZOLE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEOMYCIN; ORNITHINE ASPARTATE; PAROMOMYCIN; PROBIOTIC AGENT; PSYCHOTROPIC AGENT; RIFAXIMIN; VANCOMYCIN;

ABDOMINAL CRAMP; ALGORITHM; AMMONIA BLOOD LEVEL; ANTIBIOTIC RESISTANCE; CAR DRIVING; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET THERAPY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FLATULENCE; FUNCTIONAL DISEASE; GOLD STANDARD; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER FAILURE; MALABSORPTION; NEPHROTOXICITY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; OTOTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCREENING; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 34548185116     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984576     Document Type: Review

References (97)

1. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- definifion, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721
2. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-559
3. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998;28:45-49
4. Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States: an AASLD survey. Hepatology 2007;45:833-834
5. Zeneroli ML, Cioni G, Vezzelli C, et al. Prevalence of brain atrophy in liver cirrhosis patients with chronic persistent encephalopathy: evaluation by computed tomography. J Hepatol 1987;4:283-292
6. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295-2304
7. Shawcross DL, Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis 2005;20:169-179
8. Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:95-110
9. Keiding S, Sorensen M, Bender D, et al. Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 2006;43:42-50
10. Lockwood AH. Positron emission tomography in the study of hepatic encephalopathy. Metab Brain Dis 1998;13:303-309
11. Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006;55:98-104
12. Clemmesen JO, Larsen FS, Kondrup J, et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999;29: 648-653
13. Kundra A, Jain A, Banga A, et al. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin Biochem 2005;38:696-699
14. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-254
15. Mullen KD. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1): 11-16
16. Amodio P, Montagnese S, Gatta A, Morgan MY. Characteristics of minimal hepatic encephalopathy. Metab Brain Dis 2004;19:253-267
17. Mattarozzi K, Campi C, Guarino M, Stracciari A. Distinguishing between clinical and minimal hepatic encephalopathy on the basis of specific cognitive impairment. Metab Brain Dis 2005;20:243-249
18. Weissenborn K, Giewekemeyer K, Heidenreich S, et al. Attention, memory, and cognitive function in hepatic encephalopathy. Metab Brain Dis 2005;20:359-367
19. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96:2718-2723
20. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000;95:2029-2034
21. Das A, Dhiman RK, Saraswat VA, et al. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001;16:531-535
22. Saxena N, Bhatia M, Joshi YK, et al. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver 2002;22:190-197
23. Schomerus H, Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001; 16:37-41
24. Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005;42(suppl):S45-S53
25. Amodio P, Del Piccolo F, Marchetti P, et al. Clinical features and survival of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999;29:1662-1667
26. Howanitz JH, Howanitz PJ, Skrodzki CA, Iwanski JA. Influences of specimen processing and storage conditions on results for plasma ammonia. Clin Chem 1984;30:906-908
27. Barsotti RJ. Measurement of ammonia in blood. J Pediatr 2001;138:S11-S19
28. Weissenborn K, Ennen JC, Schomerus H, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001;34:768-773
29. Weissenborn K, Heidenreich S, Ennen J, et al. Attention deficits in minimal hepatic encephalopathy. Metab Brain Dis 2001;16:13-19
30. Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977;22:541-550
31. Vergara-Gomez M, Flavia-Olivella M, Gil-Prades M, et al. [Diagnosis and treatment of hepatic encephalopathy in Spain: results of a survey of hepatologists]. Gastroenterol Hepatol 2006;29:1-6
32. Amodio P, Marchetti P, Del Piccolo F, et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 1999;110:1334-1344
33. Butterworth RE. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003;39:278-285
34. Kullmann F, Hollerbach S, Holstege A, Scholmerich J. Subclinical hepatic encephalopathy: the diagnostic value of evoked potentials. J Hepatol 1995;22:101-110
35. Stewart CA, Reivich M, Lucey MR, Gores GJ. Neuroimaging in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005;3:197-207
36. Yang SS, Wu CH, Chiang TR, Chen DS. Somatosensory evoked potentials in subclinical portosystemic encephalopathy: a comparison with psychometric tests. Hepatology 1998;27:357-361
37. Romero-Gomez M, Cordoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007;45:879-885
38. Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002;35:357-366
39. Montagnese S, Gordon HM, Jackson C, et al. Disruption of smooth pursuit eye movements in cirrhosis: relationship to hepatic encephalopathy and its treatment. Hepatology 2005;42:772-781
40. Bajaj JS, Saeian K, Verber MD, et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol 2007;102:754-760
41. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis 1978;23:398-406
42. Conn H, Lieberthal MM. Hepatic Coma Syndromes and Lactulose. Baltimore: Lippincott Williams & Wilkins; 1979
43. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. Lancet 1974;2:81-84
44. Amodio P, Pellegrini A, Ubiali E, et al. The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clin Neurophysiol 2006;117: 2243-2251
45. Pellegrini A, Ubiali E, Orsato R, et al. Electroencephalographic staging of hepatic encephalopathy by an artificial neural network and an expert system. Neurophysiol Clin 2005;35:162-167
46. Blei AT. Treatment of hepatic encephalopathy. Lancet 2005;365:1383-1384
47. Arria AM, Tarter RE, Starzl TE, Van Thiel DH. Improvement in cognitive functioning of alcoholics following orthotopic liver transplantation. Alcohol Clin Exp Res 1991;15:956-962
48. Mattarozzi K, Stracciari A, Vignatelli L, et al. Minimal hepatic encephalopathy: longitudinal effects of liver transplantation. Arch Neurol 2004;61:242-247
49. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. Gastroenterology 1977;72:573-583
50. Blanc P, Daures JP, Rouillon JM, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992;15:222-228
51. Camma C, Fiorello F, Tine F, et al. Lactitol in treatment of chronic hepatic encephalopathy: a meta-analysis. Dig Dis Sci 1993;38:916-922
52. Morgan MY, Hawley KE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 1987;7:1278-1284
53. Uribe M, Marquez MA, Garcia-Ramos G, et al. Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients. Dig Dis Sci 1980;25:924-928
54. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev 2004;(2):CD003044
55. Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981;26:498-506
56. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-545
57. Tromm A, Griga T, Greving I, et al. Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000; 47:473-477
58. Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut 1982;23:1-7
59. Tarao K, Ikeda T, Hayashi K, et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990;31:702-706
60. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118
61. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58
62. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208
63. Di Piazza S, Gabriella FM, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991;23:403-407
64. Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-178
65. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007;52:737-741
66. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006;38:3552-3555
67. Spiegel B, Huang E, Esrailian E. Is rifaximin cost-effective in the management of hepatic encephalopathy? Gastroenterology 2006;130:A-806. Abstract M1031
68. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-378
69. Cadranel JF, el Younsi M, Pidoux B, et al. Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 1995;7:325-329
70. Gyr K, Meier R, Haussler J, et al. Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996;39:319-324
71. Pomier-Layrargues G, Giguere JF, Lavoie J, et al. Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology 1994; 19:32-37
72. Van der Rijt CC, Schalm SW, Meulstee J, Stijnen T. Flumazenil therapy for hepatic encephalopathy: a double-blind cross over study. Gastroenterol Clin Biol 1995;19:572-580
73. Goulenok C, Bernard B, Cadranel JF, et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002;16:361-372
74. Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 1989;96:240-243
75. Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005;3:184-191
76. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997;25:1351-1360
77. Staedt U, Leweling H, Gladisch R, et al. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis: a double-blind, randomized study using a four-fold crossover design. J Hepatol 1993;19:424-430
78. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-864
79. Poo JL, Gongora J, Sanchez-Avila F, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy: results of a randomized, lactulose-controlled study. Ann Hepatol 2006;5:281-288
80. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-643
81. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38-43
82. Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2007;25(suppl 1):23-31
83. Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006;136:295S-298S
84. Khanna S, Gopalan S. Role of branched-chain amino acids in liver disease: the evidence for and against. Curr Opin Clin Nutr Metab Care 2007;10:297-303
85. Therrien G, Rose C, Butterworth J, Butterworth RF. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. Hepatology 1997;25:551-556
86. Malaguarnera M, Pistone G, Elvira R, et al. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005;11:7197-7202
87. Malaguarnera M, Pistone G, Astuto M, et al. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 2006;51:2242-2247
88. Siciliano M, Annicchiarico BE, Lucchese F, Bombardieri G. Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic patients with hepatic encephalopathy. Clin Exp Pharmacol Physiol 2006;33:76-80
89. Vogels BA, Maas MA, Daalhuisen J, et al. Memantine, a noncompetitive NMDA receptor antagonist improves hyper-ammonemia-induced encephalopathy and acute hepatic encephalopathy in rats. Hepatology 1997;25:820-827
90. Yurdaydin C, Herneth AM, Puspok A, et al. Modulation of hepatic encephalopathy in rats with thioacetamide-induced acute liver failure by serotonin antagonists. Eur J Gastroenterol Hepatol 1996;8:667-671
91. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976
92. Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003;48:1622-1626
93. Harcourt Test Services. PSE syndrome test. Available at: http.7/www.harcourt.de/front_content.php?idcat=18&idart=63. Accessed April 19, 2007
94. Harcourt Assessment. Wechsler Adult Intelligence Scale-Third Edition (WAIS-III). Available at: http://harcourtassessment.com/HAIWEB/Cultures/en-us/ Productdetail.htm?Pid=015-8980-727&Mode=summary. Accessed April 19, 2007
95. Duphalac. Number connection A test. Available at: http://www.duphalac. com/professionals/portosystemicencephalopathy/psetest/0,10319-2-0,00.htm. Accessed April 19, 2007
96. Bajaj JS, Hafeezullah M. Minimal hepatic encephalopathy, a vehicle for accidents and violations: the reality beyond the driving test. Hepatology 2006;44:233A (abstract 120)
97. Wein C, Koch H, Popp B, et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004;39:739-745